Summary: The most important drugs in COPD therapy are long-acting b2-agonists (LABA), long-acting muscarinic antagonists (LAMA) and inhaled corticosteroids (ICS). Role of the last is still investigated. In current practice physicians use different combinations of them. In moderate to severe COPD therapy with all three of them can be introduced and we call it triple therapy. Latest edition of GOLD recommends it for patients with insufficient control of symptoms and reduction of exacerbations despite current treatment. Clinical trials proved superiority of triple therapy in terms of lung function improvement and reduction of exacerbations comparing with LAMA + LABA and LABA + ICS treatments. Moreover, it has been proved that triple therapy in one inhaler is not inferior to LAMA + LABA/ICS from separated ones. Considering possible adverse effects of triple therapy such as higher incidence of pneumonia and still insufficient evidence, further trials are needed. Lately several research papers confirmed usefulness of peripheral blood eosinophils as indicator for introduction of ICS in therapy. In GOLD recommendations physicians can now find thresholds helpful in such assessment. Similarly to triple therapy, we still need more evidence of effectiveness of peripheral blood eosinophils. Other possible indicators are currently under investigation.